Overview
Study Evaluating PSI-697 in Patients With Scleritis
Status:
Terminated
Terminated
Trial end date:
2007-04-01
2007-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate the safety of an orally administered single dose of PSI-697 in subjects with scleritis, as a model of inflammatory disease. To evaluate by in vivo confocal microscopy (IVCM) the effect of a single dose of PSI-697 on leukocyte rolling in the scleral blood vessels of subjects with scleritis.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Criteria
Inclusion: Age 18 or higher; A negative urine pregnancy test at screening for femalesubjects; Female subjects must be postmenopausal or surgically sterile.
Exclusion: Isolated episcleritis; Isolated posterior scleritis; Infectious scleritis.